RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSIS

Objective: To determine the effectiveness of rifaximin in reducing the frequency of recurrence of hepatic encephalopathy among patients with liver cirrhosis. Study Design: Descriptive case series. Place and Duration of Study: Outpatient department of Combined Military Hospital Peshawar from Ja...

Full description

Bibliographic Details
Main Authors: Muhammad Zulqurnain Saleem, Muhammad Hasan Saleem, Husnain Saleem, Muhammad Ali Aasil
Format: Article
Language:English
Published: Army Medical College Rawalpindi 2021-08-01
Series:Pakistan Armed Forces Medical Journal
Subjects:
Online Access:https://pafmj.org/index.php/PAFMJ/article/view/2481
id doaj-92a57b0869d54028872f08f6359524e6
record_format Article
spelling doaj-92a57b0869d54028872f08f6359524e62021-10-06T08:47:36ZengArmy Medical College RawalpindiPakistan Armed Forces Medical Journal0030-96482411-88422021-08-0171412969910.51253/pafmj.v71i4.24812481RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSISMuhammad Zulqurnain Saleem0Muhammad Hasan Saleem1Husnain Saleem2Muhammad Ali Aasil377 Medical Battalion, PakistanPak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi PakistanCombined Military Hospital Peshawar/National University of Medical Sciences (NUMS) PakistanLahore General Hospital, Lahore PakistanObjective: To determine the effectiveness of rifaximin in reducing the frequency of recurrence of hepatic encephalopathy among patients with liver cirrhosis. Study Design: Descriptive case series. Place and Duration of Study: Outpatient department of Combined Military Hospital Peshawar from Jan to Jun 2017. Methodology: We included one hundred patients of either gender having liver cirrhosis with child Pugh B or C class with at least two previous episodes of hepatic encephalopathy. Patients were followed for six months to have any recurrence of hepatic encephalopathy. Conventional group was defined as having standard regimen including lactulose. Rifaximin treatment was defined as a 550mg BD daily dosing along with standard prescription. Results: Fifty patients were on conventional treatment to prevent recurrence of hepatic encephalopathy while 50 patients were using rifaximin in addition to standard prescription. The average age of 54.8 ± 6.1 years with 58% male patients and 48% in child-pugh B class. Thirty (30%) patients developed hepatic encephalopathy among the study population. 14 patients with recurrence belong to rifaximin group while 16 were on conventional treatment (p-value >0.05) showing a non-significant difference. Post stratification revealed only age as a significant predictor of recurrence of hepatic encephalopathy in our study population (p<0.05). Conclusion: Frequency of hepatic encephalopathy is similar in conventional treatment with Lactulose over six months of follow up as compared with rifaximin.https://pafmj.org/index.php/PAFMJ/article/view/2481decompensated liver diseasehepatic encephalopathyrifaximinlactulose
collection DOAJ
language English
format Article
sources DOAJ
author Muhammad Zulqurnain Saleem
Muhammad Hasan Saleem
Husnain Saleem
Muhammad Ali Aasil
spellingShingle Muhammad Zulqurnain Saleem
Muhammad Hasan Saleem
Husnain Saleem
Muhammad Ali Aasil
RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSIS
Pakistan Armed Forces Medical Journal
decompensated liver disease
hepatic encephalopathy
rifaximin
lactulose
author_facet Muhammad Zulqurnain Saleem
Muhammad Hasan Saleem
Husnain Saleem
Muhammad Ali Aasil
author_sort Muhammad Zulqurnain Saleem
title RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSIS
title_short RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSIS
title_full RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSIS
title_fullStr RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSIS
title_full_unstemmed RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSIS
title_sort rifaximin effectiveness in preventing the recurrence of hepatic encephalopathy among patients with liver cirrhosis
publisher Army Medical College Rawalpindi
series Pakistan Armed Forces Medical Journal
issn 0030-9648
2411-8842
publishDate 2021-08-01
description Objective: To determine the effectiveness of rifaximin in reducing the frequency of recurrence of hepatic encephalopathy among patients with liver cirrhosis. Study Design: Descriptive case series. Place and Duration of Study: Outpatient department of Combined Military Hospital Peshawar from Jan to Jun 2017. Methodology: We included one hundred patients of either gender having liver cirrhosis with child Pugh B or C class with at least two previous episodes of hepatic encephalopathy. Patients were followed for six months to have any recurrence of hepatic encephalopathy. Conventional group was defined as having standard regimen including lactulose. Rifaximin treatment was defined as a 550mg BD daily dosing along with standard prescription. Results: Fifty patients were on conventional treatment to prevent recurrence of hepatic encephalopathy while 50 patients were using rifaximin in addition to standard prescription. The average age of 54.8 ± 6.1 years with 58% male patients and 48% in child-pugh B class. Thirty (30%) patients developed hepatic encephalopathy among the study population. 14 patients with recurrence belong to rifaximin group while 16 were on conventional treatment (p-value >0.05) showing a non-significant difference. Post stratification revealed only age as a significant predictor of recurrence of hepatic encephalopathy in our study population (p<0.05). Conclusion: Frequency of hepatic encephalopathy is similar in conventional treatment with Lactulose over six months of follow up as compared with rifaximin.
topic decompensated liver disease
hepatic encephalopathy
rifaximin
lactulose
url https://pafmj.org/index.php/PAFMJ/article/view/2481
work_keys_str_mv AT muhammadzulqurnainsaleem rifaximineffectivenessinpreventingtherecurrenceofhepaticencephalopathyamongpatientswithlivercirrhosis
AT muhammadhasansaleem rifaximineffectivenessinpreventingtherecurrenceofhepaticencephalopathyamongpatientswithlivercirrhosis
AT husnainsaleem rifaximineffectivenessinpreventingtherecurrenceofhepaticencephalopathyamongpatientswithlivercirrhosis
AT muhammadaliaasil rifaximineffectivenessinpreventingtherecurrenceofhepaticencephalopathyamongpatientswithlivercirrhosis
_version_ 1716841013944778752